Pietrzak Jacek, Wosiak Agnieszka, Szmajda-Krygier Dagmara, Świechowski Rafał, Łochowski Mariusz, Pązik Milena, Balcerczak Ewa
Laboratory of Molecular Diagnostics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, BRaIN Laboratories, Medical University of Lodz, Czechoslowacka 4, 92-216 Lodz, Poland.
Department of Thoracic Surgery, Copernicus Memorial Hospital, Medical University of Lodz, Pabianicka 62, 93-513 Lodz, Poland.
Biomedicines. 2023 Jun 21;11(7):1777. doi: 10.3390/biomedicines11071777.
In the course of lung cancer, normal cells are transformed into cancerous ones, and changes occur in the microenvironment, including the extracellular matrix (ECM), which is not only a scaffold for cells, but also a reservoir of cytokines, chemokines and growth factors. Metalloproteinases (MMPs) are among the elements that enable ECM remodeling. The publication focuses on the problem of changes in the gene expression of , and tissue inhibitor of metalloproteinases () in the blood of NSCLC patients during therapy (one year after surgical resection of the tumor). The paper also analyzes differences in the expression of the studied genes in the tumor tissue, as well as data collected in publicly available databases. The results of blood tests showed no differences in the expression of the tested genes during therapy; however, changes were observed in cancerous tissue, which was characterized by higher expression of and , compared to non-cancerous tissue, and unchanged expression of . Nevertheless, higher expression of each of the studied genes was associated with shorter patient survival. Interestingly, it was not only the increased expression of metalloproteinase genes, but also the increased expression of the metalloproteinase inhibitor () that was unfavorable for patients.
在肺癌发展过程中,正常细胞会转变为癌细胞,微环境也会发生变化,包括细胞外基质(ECM),它不仅是细胞的支架,还是细胞因子、趋化因子和生长因子的储存库。金属蛋白酶(MMPs)是促使ECM重塑的因素之一。该出版物聚焦于非小细胞肺癌(NSCLC)患者在治疗期间(肿瘤手术切除一年后)血液中金属蛋白酶、 以及金属蛋白酶组织抑制剂()基因表达变化的问题。论文还分析了所研究基因在肿瘤组织中的表达差异,以及从公开可用数据库中收集的数据。血液检测结果显示,治疗期间所检测基因的表达没有差异;然而,在癌组织中观察到了变化,与非癌组织相比,癌组织中 和 的表达更高,而 的表达没有变化。尽管如此,所研究的每个基因的高表达都与患者较短的生存期相关。有趣的是,不仅金属蛋白酶基因的表达增加对患者不利,金属蛋白酶抑制剂()表达的增加同样不利。